Tijana Brien

Cooley advised Eagle Pharmaceuticals, a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, on its cooperation agreement with Nantahala Capital Management, a holder of approximately 38% of Eagle’s outstanding shares.

Cooley successfully secured a complete win on behalf of Beyond Inc. (formerly known as Overstock.com) and certain officers and directors, in In re Overstock Securities Litigation, when the US Court of Appeals for the 10th Circuit affirmed the district court’s dismissal of all claims. The Cooley team included John Dwyer, Tijana Brien, Heather Spears, and Rebecca Ferrari.

Cooley successfully secured the complete dismissal of a derivative action for FibroGen – a biopharmaceutical company that discovers and develops medicines for the treatment of anemia, cancer and fibrotic disease – as well as certain officers and directors. The case is In re FibroGen Inc. Derivative Litigation, C.A. No. 2022-0331-SG (Del. Ch.).

Cooley advised Reverence Capital Partners’ portfolio company Transact Campus, an innovative campus technology and payment solutions company, on a definitive agreement signed by Reverence Capital Partners to sell Transact to Roper Technologies for $1.6 billion.

Cooley secured a key win on behalf of Talphera (formerly known as AcelRx Pharmaceuticals), a Silicon Valley-based specialty pharmaceutical company focused on the development and commercialization of innovative therapies, in a securities class action lawsuit brought by investors.